Prodrug form

A prodrug form is a pharmacologically inactive or less active compound that must undergo a chemical or enzymatic transformation within the body to release its active drug moiety (NCI Dictionary of Cancer Terms). This strategy is primarily employed in drug design to enhance the pharmacokinetic profile of a therapeutic agent, such as improving oral bioavailability, increasing water solubility, or facilitating site-specific delivery (Rautio et al., Nature Reviews Drug Discovery, 2008). Common examples include Enalapril, which is converted to Enalaprilat, and Valacyclovir, which is converted to Acyclovir (StatPearls, NBK538155). Because the activation process often relies on specific host enzymes like Cytochrome P450 or esterases, the therapeutic efficacy of a prodrug can be significantly affected by genetic polymorphisms or liver function (PubMed, PMID: 29485315). While the term describes a drug's chemical state rather than a biological target like a receptor or enzyme, it is a fundamental concept in modern pharmacology used to overcome delivery challenges and reduce systemic side effects. The design of a prodrug involves attaching a 'promoiety' to the active drug, which is then cleaved in vivo to trigger the pharmacological effect. This approach can also be used to mask bitter tastes or reduce irritation at the site of injection. Understanding the metabolic pathway of a prodrug is essential for predicting potential drug-drug interactions and ensuring patient safety.

Other names

ProdrugPro-drugBioreversible derivativeLatentiated drug

Prodrugs undergo in vivo enzymatic or chemical transformation to release the pharmacologically active parent drug (StatPearls, NBK538155).